Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $24 price target on Halozyme Therapeutics (NASDAQ: HALO) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE